// App-Quantinova.ai

2693 : Longitudinal Assessment of Thrombin Generation in Patients with Hemophilia Receiving Fitusiran Prophylaxis: Phase II Study Results

Researchers

Presenter

  • Claude Ngrier

Principal Investigators

  • Margaret V. Ragni

  • John Pasi

  • Steven W. Pipe

  • Gili Kenet

  • Savita Rangarajan

  • Salim Kichou

  • Baisong Mei

  • Shauna R. Andersson

Medical Centers

  • Hôpital Cardiologique Louis Pradel, Lyon, France

  • Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

  • Royal London Haemophilia Centre, Barts and the London School of Medicine and Dentistry, London, United Kingdom

  • Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI

  • Israel National Hemophilia Center and Thrombosis Unit, Chaim Sheba Medical Centre, Tel‐Hashomer, Israel

  • Guy's & St. Thomas' NHS Foundation Trust, Basingstoke, ENG, United Kingdom

  • Sanofi, Cambridge, MA

Locations

  • France

  • United States

  • United Kingdom

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • Catalase

Drug/Treatment

  • Evithrom

Outcome

  • N/A

Study Design

  • Open Label

  • Dose Escalation

Phase

  • II

Study Id's

  • NCT02554773

  • NCT02035605

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved